KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Change in Cash (2016 - 2025)

Abbott Laboratories' Change in Cash history spans 17 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Change in Cash rose 1643.1% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $906.0 million, up 25.83%, while the annual FY2025 figure was $906.0 million, 25.83% up from the prior year.
  • Change in Cash for Q4 2025 was $1.0 billion at Abbott Laboratories, up from $560.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $1.3 billion in Q2 2022 and bottomed at -$2.1 billion in Q1 2022.
  • The 5-year median for Change in Cash is $458.0 million (2021), against an average of $84.2 million.
  • The largest annual shift saw Change in Cash plummeted 274.67% in 2022 before it skyrocketed 1643.1% in 2025.
  • A 5-year view of Change in Cash shows it stood at $497.0 million in 2021, then crashed by 42.05% to $288.0 million in 2022, then plummeted by 35.07% to $187.0 million in 2023, then tumbled by 68.98% to $58.0 million in 2024, then surged by 1643.1% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Change in Cash are $1.0 billion (Q4 2025), $560.0 million (Q3 2025), and $419.0 million (Q2 2025).